VISICOL

Visicol Adverse Events Reported to the FDA Over Time

How are Visicol adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Visicol, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Visicol is flagged as the suspect drug causing the adverse event.

Most Common Visicol Adverse Events Reported to the FDA

What are the most common Visicol adverse events reported to the FDA?

Renal Failure Acute	81 (5.15%)
Vomiting	55 (3.5%)
Nausea	51 (3.24%)
Hypoaesthesia	43 (2.74%)
Malaise	41 (2.61%)
Dehydration	38 (2.42%)
Hypocalcaemia	26 (1.65%)
Asthenia	23 (1.46%)
Hypokalaemia	21 (1.34%)
Nephrocalcinosis	21 (1.34%)
Blood Pressure Decreased	19 (1.21%)
	Show More
Renal Failure	17 (1.08%)
Tetany	17 (1.08%)
Blood Calcium Decreased	16 (1.02%)
Diarrhoea	16 (1.02%)
Abdominal Pain	15 (.95%)
Hyperphosphataemia	15 (.95%)
Decreased Appetite	14 (.89%)
Oedema Peripheral	14 (.89%)
Blood Potassium Decreased	13 (.83%)
Blood Phosphorus Increased	12 (.76%)
Dyspnoea	12 (.76%)
Electrolyte Imbalance	12 (.76%)
Loss Of Consciousness	12 (.76%)
Medication Error	12 (.76%)
Nephropathy	12 (.76%)
Renal Tubular Necrosis	12 (.76%)
Weight Increased	12 (.76%)
Abdominal Distension	11 (.7%)
Blood Creatinine Increased	11 (.7%)
Shock	11 (.7%)
Depressed Level Of Consciousness	10 (.64%)
Dizziness	10 (.64%)
Feeling Abnormal	10 (.64%)
Blood Urea Increased	9 (.57%)
Convulsion	9 (.57%)
Cyanosis	9 (.57%)
Haemodialysis	9 (.57%)
Hyponatraemia	9 (.57%)
Hypotension	9 (.57%)
Renal Impairment	9 (.57%)
Anaemia	8 (.51%)
Body Temperature Increased	8 (.51%)
Colitis Ischaemic	8 (.51%)
Dialysis	8 (.51%)
Fatigue	8 (.51%)
Post Procedural Complication	8 (.51%)
Rash	8 (.51%)
White Blood Cell Count Increased	8 (.51%)
Cerebral Infarction	7 (.45%)
Cold Sweat	7 (.45%)
Feeling Cold	7 (.45%)
Haemorrhoids	7 (.45%)
Headache	7 (.45%)
Anxiety	6 (.38%)
Blood Pressure Increased	6 (.38%)
Drug Dispensing Error	6 (.38%)
Electrocardiogram Qt Prolonged	6 (.38%)
Foreign Body Trauma	6 (.38%)
Generalised Oedema	6 (.38%)
Infrequent Bowel Movements	6 (.38%)
Metabolic Acidosis	6 (.38%)
Pyrexia	6 (.38%)
Cardiomegaly	5 (.32%)
Colitis	5 (.32%)
Disorientation	5 (.32%)
Fall	5 (.32%)
Grand Mal Convulsion	5 (.32%)
Haematochezia	5 (.32%)
Heart Rate Increased	5 (.32%)
Hypertriglyceridaemia	5 (.32%)
Kidney Enlargement	5 (.32%)
Muscular Weakness	5 (.32%)
No Therapeutic Response	5 (.32%)
Oesophageal Obstruction	5 (.32%)
Oesophagitis	5 (.32%)
Proctalgia	5 (.32%)
Pseudocyst	5 (.32%)
Refusal Of Treatment By Patient	5 (.32%)
Swelling Face	5 (.32%)
Urine Output Decreased	5 (.32%)
Vision Blurred	5 (.32%)
Wrong Drug Administered	5 (.32%)
Abdominal Pain Upper	4 (.25%)
Acute Prerenal Failure	4 (.25%)
Anorexia	4 (.25%)
Blood Sodium Decreased	4 (.25%)
Cardiac Failure	4 (.25%)
Chills	4 (.25%)
Colonic Polyp	4 (.25%)
Eating Disorder	4 (.25%)
Haematocrit Decreased	4 (.25%)
Labyrinthitis	4 (.25%)
Osteoarthritis	4 (.25%)
Pain	4 (.25%)
Pancreatitis Acute	4 (.25%)
Pleural Effusion	4 (.25%)
Renal Failure Chronic	4 (.25%)
Rotator Cuff Syndrome	4 (.25%)
Speech Disorder	4 (.25%)
Abasia	3 (.19%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Visicol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Visicol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Visicol

What are the most common Visicol adverse events reported to the FDA?

Gastrointestinal Signs	152 (9.67%)
Renal Disorders	142 (9.03%)
Neurological	99 (6.3%)
Electrolyte And Fluid Balance Condi...	88 (5.6%)
Bone, Calcium, Magnesium And Phosph...	63 (4.01%)
Water, Electrolyte And Mineral	56 (3.56%)
Cardiac And Vascular Investigations	47 (2.99%)
Medication Errors	31 (1.97%)
Nephropathies	30 (1.91%)
Gastrointestinal Motility And Defec...	29 (1.84%)
Renal And Urinary Tract Investigati...	28 (1.78%)
	Show More
Epidermal And Dermal Conditions	24 (1.53%)
Gastrointestinal Inflammatory Condi...	24 (1.53%)
Decreased And Nonspecific Blood Pre...	23 (1.46%)
Physical Examination Topics	23 (1.46%)
Urolithiases	23 (1.46%)
Appetite And General Nutritional	21 (1.34%)
Respiratory	20 (1.27%)
Gastrointestinal Stenosis And Obstr...	19 (1.21%)
Cardiac Arrhythmias	17 (1.08%)
Hematological And Lymphoid Tissue T...	17 (1.08%)
Gastrointestinal Ulceration And Per...	16 (1.02%)
Infections - Pathogen Unspecified	16 (1.02%)
Injuries	16 (1.02%)
Seizures	16 (1.02%)
Gastrointestinal Hemorrhages	14 (.89%)
Hematology Investigations	14 (.89%)
Musculoskeletal And Connective Tiss...	14 (.89%)
Therapeutic And Nontherapeutic Effe...	14 (.89%)
Procedural And Device Related Injur...	13 (.83%)
Anal And Rectal Conditions	12 (.76%)
Anemias Nonhemolytic And Marrow Dep...	11 (.7%)
Cardiac Disorder Signs	11 (.7%)
Lifestyle Issues	11 (.7%)
Central Nervous System Vascular	10 (.64%)
Deliria	10 (.64%)
Gastrointestinal Vascular Condition...	10 (.64%)
Joint	9 (.57%)
Skin Appendage Conditions	9 (.57%)
Movement Disorders	8 (.51%)
Salivary Gland Conditions	8 (.51%)
Vision	8 (.51%)
Headaches	7 (.45%)
Muscle	7 (.45%)
Myocardial	7 (.45%)
Urinary Tract Signs	7 (.45%)
Acid-base	6 (.38%)
Anxiety Disorders	6 (.38%)
Arteriosclerosis, Stenosis, Vascula...	6 (.38%)
Body Temperature Conditions	6 (.38%)
Exocrine Pancreas Conditions	6 (.38%)
Gastrointestinal	6 (.38%)
Heart Failures	6 (.38%)
Metabolic, Nutritional And Blood Ga...	6 (.38%)
Benign Neoplasms Gastrointestinal	5 (.32%)
Bone And Joint Injuries	5 (.32%)
Lipid Metabolism	5 (.32%)
Vulvovaginal Disorders	5 (.32%)
Bacterial Infectious	4 (.25%)
Eating Disorders	4 (.25%)
Eye	4 (.25%)
Glucose Metabolism Disorders	4 (.25%)
Oral Soft Tissue Conditions	4 (.25%)
Parathyroid Gland	4 (.25%)
Pleural	4 (.25%)
Allergic Conditions	3 (.19%)
Angiedema And Urticaria	3 (.19%)
Coronary Artery	3 (.19%)
Cranial Nerve Disorders	3 (.19%)
Embolism And Thrombosis	3 (.19%)
Enzyme	3 (.19%)
Fungal Infectious	3 (.19%)
Gallbladder	3 (.19%)
Inner Ear And Viiith Cranial Nerve	3 (.19%)
Peritoneal And Retroperitoneal Cond...	3 (.19%)
Chemical Injury And Poisoning	2 (.13%)
Diverticular	2 (.13%)
Increased Intracranial Pressure And...	2 (.13%)
Mental Impairment	2 (.13%)
Neurological, Special Senses And Ps...	2 (.13%)
Protein And Amino Acid Metabolism	2 (.13%)
Protein And Chemistry Analyses	2 (.13%)
Psychiatric	2 (.13%)
Thoracic Disorders	2 (.13%)
Uterine, Pelvic And Broad Ligament	2 (.13%)
Vascular	2 (.13%)
Viral Infectious	2 (.13%)
Cardiac Valve	1 (.06%)
Communication Disorders	1 (.06%)
Demyelinating	1 (.06%)
Depressed Mood Disorders	1 (.06%)
Gastrointestinal Neoplasms Malignan...	1 (.06%)
Gastrointestinal Therapeutic Proced...	1 (.06%)
Hepatic And Hepatobiliary	1 (.06%)
Lower Respiratory Tract Disorders	1 (.06%)
Microbiology And Serology	1 (.06%)
Mood Disorders	1 (.06%)
Neonatal Respiratory	1 (.06%)
Neuromuscular	1 (.06%)
Ocular Neuromuscular	1 (.06%)
Ocular Sensory Symptoms	1 (.06%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Visicol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Visicol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.